These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9849978)

  • 1. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX.
    Shinefield HR; Black SB; Staehle BO; Adelman T; Ensor K; Ngai A; White CJ; Bird SR; Matthews H; Kuter BJ
    Pediatr Infect Dis J; 1998 Nov; 17(11):980-5. PubMed ID: 9849978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group.
    Reuman PD; Sawyer MH; Kuter BJ; Matthews H
    Pediatr Infect Dis J; 1997 Jul; 16(7):662-7. PubMed ID: 9239770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group.
    White CJ; Stinson D; Staehle B; Cho I; Matthews H; Ngai A; Keller P; Eiden J; Kuter B
    Clin Infect Dis; 1997 May; 24(5):925-31. PubMed ID: 9142794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children.
    Shinefield HR; Black SB; Staehle BO; Matthews H; Adelman T; Ensor K; Li S; Chan I; Heyse J; Waters M; Chan CY; Vessey SJ; Kaplan KM; Kuter BJ;
    Pediatr Infect Dis J; 2002 Jun; 21(6):555-61. PubMed ID: 12182381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.
    Deichmann KA; Ferrera G; Tran C; Thomas S; Eymin C; Baudin M
    Vaccine; 2015 May; 33(20):2379-86. PubMed ID: 25765966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
    Shinefield H; Black S; Digilio L; Reisinger K; Blatter M; Gress JO; Brown ML; Eves KA; Klopfer SO; Schödel F; Kuter BJ
    Pediatr Infect Dis J; 2005 Aug; 24(8):665-9. PubMed ID: 16094217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity.
    Hesley TM; Reisinger KS; Sullivan BJ; Jensen EH; Stasiorowski S; Meechan C; Chan CY; West DJ;
    Pediatr Infect Dis J; 2004 Mar; 23(3):240-5. PubMed ID: 15014300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine.
    Obaro SK; Enwere GC; Deloria M; Jaffar S; Goldblatt D; Brainsby K; Hallander H; McInnes P; Greenwood BM; McAdam KP
    Pediatr Infect Dis J; 2002 Oct; 21(10):940-7. PubMed ID: 12394817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
    Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
    J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad).
    Kuter BJ; Brown ML; Hartzel J; Williams WR; EvesiKaren A; Black S; Shinefield H; Reisinger KS; Marchant CD; Sullivan BJ; Thear M; Klopfer S; Xu J; Gress JO; Schödel F;
    Hum Vaccin; 2006; 2(5):205-14. PubMed ID: 17035730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.
    Gillet Y; Habermehl P; Thomas S; Eymin C; Fiquet A
    BMC Med; 2009 Apr; 7():16. PubMed ID: 19366435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
    Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E
    Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
    Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines.
    Rothstein EP; Bernstein HH; Glode MP; Laussucq S; Nonenmacher J; Long SS; Hackell JG
    Am J Dis Child; 1993 Aug; 147(8):854-7. PubMed ID: 8394646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
    Vesikari T; Karvonen A; Lindblad N; Korhonen T; Lommel P; Willems P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2010 Jun; 29(6):e47-56. PubMed ID: 20508478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.
    Shinefield H; Black S; Williams WR; Marchant C; Reisinger K; Stewart T; Meissner HC; Guerrero J; Klopfer SO; Xu J; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2005 Aug; 24(8):670-5. PubMed ID: 16094218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.